학술논문

Bioluma: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer - A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition
Document Type
Journal
Source
ONCOLOGY RESEARCH AND TREATMENT; SEP 2017, 40 p92-p93, 2p. Supplement: 3
Subject
Language
English
ISSN
22965262